Bipartisan letter urges effective administration of 340B program

Aug 29, 2018 - 12:16 PM
hhs-appeal

House Energy and Commerce Committee Chairman Greg Walden, R-Ore., Energy and Commerce Committee Ranking Member Frank Pallone, Jr., D-N.J., Senate Health, Education, Labor, and Pensions Committee Chairman Lamar Alexander, R-Tenn., and Senate HELP Committee Ranking Member Patty Murray D-Wash., Aug. 27 sent a letter to the Health Resources and Services Administration urging the agency to use its existing rulemaking authority to implement regulations to better administer the 340B drug savings program. “The [D.C. District] court ruling made clear that HRSA does have regulatory authority that includes (1) establishing and implementing a binding Administrative Dispute Resolution process for the resolution of certain disputes relating to compliance with 340B Program requirements, (2) providing for the imposition of civil monetary penalties against manufacturers that knowingly and intentionally overcharge a covered entity for a 340B drug, and (3) issuing precisely defined standards of methodology for calculation of 340B ceiling prices,” the leaders wrote. 

Related News Articles

Headline
Rhode Island district court denies drug company efforts to block state’s 340B contract pharmacy law 
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
AHA says HRSA vastly underestimates costs 340B Rebate Pilot Program will inflict on hospitals, urges agency to delay implementation
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
AHA comments on CY 2026 OPPS proposed rule
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models 
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…